Regulatory Post Marketing Surveillance Study on Nexavar®

Status Completed

Clinical Trial Summary

This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar

Clinical Trial Description

The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®.

1. Unknown adverse events (in particular, serious adverse events)

2. Identification of adverse events occurred in the real practice.

3. Factors that are considered to affect on safety.

4. Factors that are considered to affect on effectiveness ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01012011
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase	N/A
Start date	September 2009
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03289533` - A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)	Phase 1
Terminated	`NCT01141478` - Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria	N/A
Recruiting	`NCT05580835` - PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma	N/A
Active, not recruiting	`NCT05389527` - Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT04560751` - TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Withdrawn	`NCT02939807` - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	Phase 2
Completed	`NCT01915602` - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2
Completed	`NCT04970212` - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting	`NCT02403544` - Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma	Phase 1
Completed	`NCT01897038` - A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma	Phase 1
Terminated	`NCT01337492` - Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)	Phase 0
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Completed	`NCT01003015` - Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma	Phase 2
Completed	`NCT00559455` - Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT00384800` - A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)	Phase 2
Terminated	`NCT00582400` - A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver	Phase 2
Completed	`NCT00056992` - Testing of ADI-PEG in Hepatocellular Carcinoma	Phase 2
Completed	`NCT02859324` - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)	Phase 1/Phase 2
Terminated	`NCT02439008` - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response	N/A
Completed	`NCT01915589` - Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2